Synairgen Share Discussion Threads

[amaretto1] 13/4/2020 19:38

It's still in risk zone... it's got to see a material benefit ... This is weeks away from that Red or Black !

[peachie 74] 13/4/2020 19:36

Perhaps just the BBs are up on all the potential here ! Let’s hope not

GLA

[peachie 74] 13/4/2020 19:34

TW renews ASTRAZENECA relationship - 09 MAR 2020Today 19:26
Southampton scientists renew strategic collaboration with AstraZeneca
09 MAR 2020


Prof Tom Wilkinson’s research group has renewed a long-standing collaboration with AstraZeneca to understand the mechanisms driving the development of chronic obstructive pulmonary disease (COPD).

Building on a four year collaboration between the two organisations, this renewed agreement will provide Prof Wilkinson’s group with funding for the next phase of the collaboration between AstraZeneca and the University of Southampton, a leading centre in understanding disease mechanisms of COPD and airway infection.

Establishing a well characterised cohort of patients with COPD has allowed these scientists to investigate differences in gene expression which drive the immune response to viral infection in COPD. Some of this work has recently been published in the American Journal of Respiratory and Critical Care Medicine.

COPD causes more than three million deaths a year worldwide. It is a major driver to hospital admissions and unscheduled visits to Primary Care. New treatments are desperately needed to improve outcomes for patients with the condition and this project will focus on that goal.

Tom Wilkinson, Professor of Respiratory Medicine and Lead for COPD research at the University of Southampton, said: “I am really excited about continuing this important collaboration.

"This programme of research aims to provide ground-breaking insights into disease mechanisms of COPD and will help us work towards the development of a new generation of therapies which are greatly needed for our patients.”

Maria Belvisi, Senior Vice President and Head of Early Research and Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, commented: “Through this collaboration we will continue our multi-omics analysis of COPD patient samples, and I hope this will help us identify novel patient phenotypes and previously unknown pathways that lead to this chronic disease."

By further increasing our understanding of the underlying biological drivers of COPD, we aim to develop a new generation of medicines that could modify the disease.”

[peachie 74] 13/4/2020 19:34

Some interesting stuff being discussed....

The £3.60 FinnCap target is WITHOUT any form of Global Distribution deal with the likes of ASTRAZENECA or MERCK who will be needed to distribute SNG001 globally.

Remember, SNG previously had a $232m deal with Astrazeneca which fell through in 2017. This was *BEFORE* SNG carried out any of the trials since 2017.

Even more importantly, on 09 Mar 2020, Prof Tom Wilkinson’s (SNG001 lead scientist) research group renewed a long-standing collaboration with AstraZeneca to understand the mechanisms driving the development of chronic obstructive pulmonary disease (COPD) at Southampton Hospital . ( )So Astrazeneca are ALREADY at Southampton Hospital alongside Prof Tom Wilkinson.Obviously they have now moved on to Covid-19 trials now.

So if Astrazeneca were prepared to pay SNG up to $232m over 3 years ago without any clinical trials taking place then how much will they after 3 years of trials AND a Covid-19 treatment should it be successful ?

The £3.60 target is also WITHOUT any future Worldwide stockpiling in which Finncap allude to in their note which give the current example of the Tamiflu stockpiling worth in EXCESS of $3 billion. So what price for that on top of everything else ?

FINCAP NOTE - 26 MAR 2020
"Not only would a positive trial help to address the current COVID-19 crisis but it could also offer governments the opportunity to stockpile a broad-spectrum antiviral product for future pandemics in the way that the US and European governments stockpiled significant levels of the antiviral, Tamiflu (>$3bn)."

For me,if this works, then it's easily £5-£10/share with a deal with a Global Distribution partner and i wonder who that might be ?

[amaretto1] 13/4/2020 19:33

Talking to a DR today Those recovering are suffering from breathing difficulties .. damaged lungs ... fibrosis All company's connected to this, will see a serious upserge.

[cambradjones] 13/4/2020 19:16

I had intended to sell here around the mid 90,s (if the share price gets there), as we all know round figures attract sellers.However seeing nyct smash through £4 and then £5 minutes later I'm not so sure.Corona related stocks in demand at the mo for obvious reasons so we could end up anywhere prior to test results.Gla

[kop202] 13/4/2020 19:01

JevDefinitely but if the results are that good...... who would sell..

[jev1] 13/4/2020 18:50

Post 3390

On that basis, conversely, the following statement would also apply:

"It's clear then if the pilot study does throw up a statistically significant positive result the MM's will set to work increasing the share price by a substantial amount.....it will definitely be a time to buy and sell back when the share price is far higher imo ."

[kop202] 13/4/2020 18:47

I suppose it all depends how the results are interpreted by people like Nobby. The world is desperate for some sort of effective treatment. I wonder what sort of time frame we would be looking at for the results of the 400 patient trial?

[kop202] 13/4/2020 18:40

It's clear then if the pilot study does not throw up a statistically significant positive result the MM's will set to work reducing the share price by a substantial amount.....it will definitely be a time to sell and buy back cheaper imo .

[the patient investor] 13/4/2020 17:59

lithy

do not laugh


we are both on probation

[the patient investor] 13/4/2020 16:53

drunk already

[nobbygnome] 13/4/2020 15:30

So to be clear I expect the result of the 100 patient (50 on drug and 50 on placebo) pilot study towards the end of May. In theory those results should then educate whether to go ahead with the larger trial and under what conditions. However, if the result is statistically significant what I expect will actually happen is that there will be overwhelming pressure on the regulators to give the drug an expedited conditional approval. In addition, I would expect the FDA to facilitate an EUA for the drug.

But to be clear this requires a clear statistically significant result and is just IMHO. I could easily be wrong.

[801710245] 13/4/2020 15:20

Nobby,

Please, for clarification: Your 3363 posted at 10:51, regarding the expanded trial:-

If the 50 of the initial 100 patients taking part, who were administered SNG001 fair substantially better than those given the placebo, do you expect an RNS to inform the market before the other 300 join the trial - or is it the result of all 400 (200 with, 200 without), towards the end of May that will be 'RNS'd'?

Put simply, should we expect an interim statement before the end of May?

[d1nga] 13/4/2020 15:19

Saudis trial link

[wetdream] 13/4/2020 14:10

I wonder if AZN has ‘first refusal’ on SNG001, even though they handed it back to Synairgen?
Imho it’s likely that the headlines following a renewed partnership with such a global player will shift the share price rather than the statistical significance of outcome data from these complex drug trials.

[torreskid] 13/4/2020 13:54

Great find Likya

Suggests IFN shifts the curve to the left, therefore reducing the severity/extent of disease process, which would imply that used early on (as a prophylactic treatment and beyond) in the course of pandemic, may reduce hospital admissions and ultimately death.

Could this be the 'aspirin' of respiratory viral infections?

[pdt] 13/4/2020 13:44

Excellent find. Thanks for posting Likya

Now with some evidence of efficacy using inhaled IFN alpha in Covid patients we should be encouraged for results in IFN beta 1a being used by SNG, which research suggests should be the better subtype candidate for therapy. Also SNG are ahead being in a placebo controlled trial with prior safety data.

Great having this board to feed us all the bits of the puzzle. Well done Nobby.